Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,473.47
(
0.37%
)
US TECH 100
28,612.40
(
0.11%
)
Dow Jones
50,579.70
(
0.58%
)
Brent Oil
94.98
(
-6.12%
)
Bitcoin
76,455.06
(
-1.06%
)
News Focus
News Focus
Post# of 4522
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

No-dough-go

Send PM Follow Ignore
Followers 9
Posts 601
Boards Moderated 0
Alias Born 12/09/2011

No-dough-go

Re: ronpopeil post# 1348

Tuesday, 03/13/2012 3:14:02 PM

Tuesday, March 13, 2012 3:14:02 PM

Post# of 4522
What about this Ron?

In the U.S., Threshold will be responsible for the development of TH-302 in the soft tissue sarcoma indication, while both companies will jointly develop the drug in all other cancer indications. Merck KGaA will pay 70% of worldwide development costs for TH-302.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today